Description:
<jats:p>
The renin-angiotensin system (RAS) participates in preeclampsia; however, the relative contributions from the circulating RAS and the tissue-based, uteroplacental RAS are unknown. We hypothesized that the tissue-based uteroplacental RAS is dysregulated in preeclampsia. We performed microarray and gene expression studies and confirmed the findings on the protein level by immunohistochemistry in ureteroplacental units from 10 preeclamptic women and 10 women with uneventful pregnancies. All of the women were delivered by cesarean section. We also analyzed plasma renin activity and circulating agonistic angiotensin II type 1 (AT
<jats:sub>1</jats:sub>
) receptor autoantibodies. In preeclampsia, we found that the angiotensin II AT
<jats:sub>1</jats:sub>
receptor gene was 5-fold upregulated in decidua (maternal origin). We also found AT
<jats:sub>1</jats:sub>
autoantibodies in preeclamptic women and in their offspring by neonatal cardiomyocyte bioassay compared with women with normal pregnancies and their infants (mother: 17.5±2.2 versus 0.05±0.4; fetus: 14.5±1.8 versus 0.5±0.5 Δbpm). Gene expressions for renin (35.0-fold), angiotensin-converting enzyme (2.9-fold), and angiotensinogen (8.9-fold) were higher in decidua than placenta (fetal origin) in both control and preeclamptic women, whereas the AT
<jats:sub>1</jats:sub>
receptor was expressed 10-fold higher in placenta than in decidua in both groups. Our findings elucidate the ureteroplacental unit RAS in preeclamptic and normal pregnancies. We found that, in preeclampsia, the AT
<jats:sub>1</jats:sub>
receptor expression is particularly high in decidua, combined with pregnancy-specific tissue RAS involving decidual angiotensin II production and AT
<jats:sub>1</jats:sub>
autoantibodies. We also showed that AT
<jats:sub>1</jats:sub>
autoantibodies cross the ureteroplacental barrier. These components could participate in the pathophysiology of preeclampsia.
</jats:p>